There’s a pattern that keeps showing up here — posts that start off sounding “neutral” or “just sharing thoughts” but end up spreading the same skepticism, frustration, and doubt. You can tell a lot from tone and word choice. When someone says they’re not trying to change anyone’s belief, that’s usually the setup for exactly that — an attempt to sway confidence by dressing negativity up as balance.
Pointing out that some made money in 2021 and others didn’t isn’t insight, it’s hindsight. Everyone made their own decisions based on the information and belief they had at the time. Bringing that up again now adds nothing except another reminder of past frustration.
Calling Dr. Dalton’s statements “rhetoric” is also a subtle dig meant to make shareholders feel foolish for believing in the vision. But if this were the typical OTC pump-and-dump playbook, we would have seen constant hype, daily posts, exaggerated PR, and quick dilution long ago. That’s not what’s happened here. The quiet periods and long silences are exactly what you’d expect from something real being built behind the scenes — not a flash scam.
Questioning why there isn’t a weekly breakdown of accomplishments misses how OTC development works. Most serious partnerships, filings, and corporate moves happen privately until the structure and timing are right. That’s not “lack of transparency”; that’s how you protect value and prevent premature leaks.
Now, I’m not cheerleading, and I’m not saying that everything has been done the way I would have liked it to be done. I would have liked more communication and more updates, like most of us. But we’re all in this, we all made our own decisions, and at this point, grounded optimism makes more sense than recycled skepticism. Looking at the big picture, there are reasons for optimism. The structure, the timing, and the signals all feel different now. We’re not blind followers; we’re realistic long-term investors who still see the potential that first drew us here.
A new week is ahead, yes — but some of us are walking into it with patience and quiet confidence, not the same tired negativity.
Pointing out that some made money in 2021 and others didn’t isn’t insight, it’s hindsight. Everyone made their own decisions based on the information and belief they had at the time. Bringing that up again now adds nothing except another reminder of past frustration.
Calling Dr. Dalton’s statements “rhetoric” is also a subtle dig meant to make shareholders feel foolish for believing in the vision. But if this were the typical OTC pump-and-dump playbook, we would have seen constant hype, daily posts, exaggerated PR, and quick dilution long ago. That’s not what’s happened here. The quiet periods and long silences are exactly what you’d expect from something real being built behind the scenes — not a flash scam.
Questioning why there isn’t a weekly breakdown of accomplishments misses how OTC development works. Most serious partnerships, filings, and corporate moves happen privately until the structure and timing are right. That’s not “lack of transparency”; that’s how you protect value and prevent premature leaks.
Now, I’m not cheerleading, and I’m not saying that everything has been done the way I would have liked it to be done. I would have liked more communication and more updates, like most of us. But we’re all in this, we all made our own decisions, and at this point, grounded optimism makes more sense than recycled skepticism. Looking at the big picture, there are reasons for optimism. The structure, the timing, and the signals all feel different now. We’re not blind followers; we’re realistic long-term investors who still see the potential that first drew us here.
A new week is ahead, yes — but some of us are walking into it with patience and quiet confidence, not the same tired negativity.
10
1
